ALEXANDRIA, Va., Sept. 28, 2026 (GLOBE NEWSWIRE) — Burke & Herbert Financial Services Corp. (the “Company”) (Nasdaq: BHRB), the holding company for Burke & Herbert Bank & Trust Company (the “Bank”), today announced the pricing of its public offering of $100.0 million aggregate principal amount of its 7.00% Fixed-to-Floating Rate Subordinated Notes due 2036 (the “Notes”). The price to the public for the Notes is 100% of the principal amount of the Notes. The Notes will mature on October 1, 2036. Interest on the Notes initially will accrue at a rate equal to 7.00% per annum from and including September 30, 2026 to, but excluding, October 1, 2031, payable semiannually in arrears. From and including October 1, 2031 to, but excluding, October 1, 2036, or the earlier redemption date, interest will accrue at a floating rate per annum equal to the Three-Month Term SOFR, or other applicable Benchmark rate (as defined in the Notes), plus a spread of 222 basis points, payable quarterly in arrears. The Notes are intended to qualify as Tier 2 capital for regulatory purposes.

The offering is expected to close on September 30, 2026, subject to the satisfaction of customary closing conditions.

Beginning with the interest payment date of October 1, 2031 and on any interest payment date thereafter, the Company may, at its option, redeem the Notes, in whole or in part, at a redemption price equal to 100.00% of par, plus accrued and unpaid interest to but excluding the date of redemption. The Company may also redeem the Notes, in whole but not in part, at any time, including prior to October 1, 2031, upon the occurrence of certain specified events.

Keefe, Bruyette & Woods, A Stifel Company, acted as the sole book-running manager for the Notes offering.

The Company intends to use the net proceeds from this offering, plus cash on hand: (i) to repay $4.5 million aggregate principal amount of its outstanding 6.875% Subordinated Note, which matures on April 1, 2028 (the “2028 Note”); $18.1 million aggregate principal amount of its outstanding 6.00% Fixed-to-Floating Rate Subordinated Notes, which currently bear interest at the Three-Month Term SOFR plus 590 basis points and mature on July 1, 2030 (the “July 2030 Notes”); and $20.0 million aggregate principal amount of its outstanding 5.00% Fixed-to-Floating Rate Subordinated Notes, which currently bear interest at the Three-Month Term SOFR plus 475 basis points and mature on October 1, 2030 plus, in each case, accrued and unpaid interest; (ii) to potentially repay all or part of its outstanding $75.0 million aggregate principal amount of 3.25% Fixed-to-Floating Rate Subordinated Notes, which currently bear interest at the fixed rate of 3.25% per year and mature on December 1, 2031, plus accrued and unpaid interest; (iii) to potentially redeem all or part of its outstanding $15.0 million aggregate liquidation preference of 2021 Preferred Stock, which has dividends payable in arrears, when, as and if authorized and declared by the board of directors of the Company out of legally available funds, on a non-cumulative basis at the $10,000 per share purchase price, at an annual rate equal to 6.00%; and (iv) for general corporate purposes, including providing capital to the Bank to support its growth. A conditional notice of redemption was delivered to the holders of the Company’s July 2030 Notes with respect to the redemption of all of the outstanding principal amount of such notes. The redemption of the Company’s July 2030 Notes is contingent on this offering of the Notes and the amount of proceeds resulting from this offering. A notice of prepayment was delivered to the holder of the 2028 Note but is not contingent on this offering of the Notes.

The offering of the Notes is being made by means of a prospectus supplement and an accompanying base prospectus. The Company previously filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement (File No. 333-283261) and has filed a preliminary prospectus supplement to the base prospectus contained in the registration statement for the Notes to which this communication relates. The Company will file a final prospectus supplement relating to the Notes. Prospective investors should read the base prospectus contained in the registration statement, the preliminary prospectus supplement, the final prospectus supplement and the other documents the Company has filed or will file with the SEC for more complete information about the Company and the Notes offering.

Copies of these documents, when available, can be obtained for free by visiting EDGAR on the SEC’s website at www.sec.gov, or by contacting Keefe, Bruyette & Woods, Inc., toll-free at (800) 966-1559 or by emailing USCapitalMarkets@kbw.com.

No Offer or Sale

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any sale of the Notes in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering of the Notes is being made only by means of a written prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. The Notes being offered have not been approved or disapproved by any regulatory authority, nor has any such authority passed upon the accuracy or adequacy of the registration statement, the base prospectus contained in the registration statement, the preliminary prospectus supplement or the final prospectus supplement relating thereto.

About Burke & Herbert

Burke & Herbert Financial Services Corp. is the financial holding company for Burke & Herbert Bank & Trust Company. Burke & Herbert Bank & Trust Company is the oldest continuously operating bank under its original name headquartered in the greater Washington, D.C. metropolitan area. With over 100 branches across Delaware, Kentucky, Maryland, Pennsylvania, Virginia, and West Virginia, Burke & Herbert Bank & Trust Company offers a full range of business and personal financial solutions designed to meet customers’ banking, borrowing, and investment needs. Learn more at investor.burkeandherbertbank.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including with respect to (or based on) the beliefs, goals, intentions, and expectations of Burke & Herbert. Forward–looking statements are typically identified by such words as “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “will,” “should,” and other similar words and expressions, and are subject to numerous assumptions, risks, and uncertainties, which change over time. Additionally, forward-looking statements speak only as of the date they are made; Burke & Herbert does not assume any duty, and does not undertake, to update such forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events, or otherwise. Furthermore, because forward-looking statements are subject to assumptions and uncertainties, actual results or future events could differ, possibly materially, from those indicated in or implied by such forward-looking statements as a result of a variety of factors, many of which are beyond the control of Burke & Herbert. Such statements are based upon the current beliefs and expectations of the management of Burke & Herbert and are subject to significant risks and uncertainties outside of its control. Caution should be exercised against placing undue reliance on forward-looking statements.

Potential risks and uncertainties include, but are not limited to, the Company’s ability to complete the offering and to deploy the net proceeds of the offering as the Company currently expects. The Company cautions readers that the foregoing list of factors is not exclusive, is not necessarily in order of importance and readers should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and the Company does not intend to and, except as required by applicable law, disclaims any obligation to update or revise any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, unless required to do so under applicable securities laws.

Media Contact: Investor Relations 703-666-3555 bhfsir@burkeandherbertbank.com

Company highlights a significant institutional milestone, advancing its intended regulated-exchange uplist through institutional custody, deployed SVLT infrastructure, proprietary nanotechnology, international real-world asset initiatives and its ongoing IFRS audit programme

JOHANNESBURG, South Africa, Sept. 28, 2026 (GLOBE NEWSWIRE) — ProText Mobility, Inc. (OTC: TXTM) (“TXTM”) today issues its Inter-Quarter Shareholder Update, as referenced in the Company’s Q2 filings, highlighting significant developments in its institutional digital-asset infrastructure strategy, international relationships and expanding real-world asset (RWA) initiatives.

PROTEXT MOBILITY ISSUES SIGNIFICANT INTER-QUARTER SHAREHOLDER UPDATE

At the centre of this update is a development that the Company has been working toward:

ABSA BANK HAS CONFIRMED THE COMPANY’S CHAIRMAN’S PARTICIPATION AS ITS FIRST PILOT CLIENT IN ITS DIGITAL-ASSET CUSTODY ONBOARDING PROCESS.

This represents a significant milestone in TXTM’s strategy of connecting real-world assets, proprietary technology, digital tokenisation and regulated institutional financial infrastructure.

For the Company, institutional custody represents a critical component of its broader roadmap. The objective has never been simply to create digital tokens.
It has been to develop the technological, commercial and institutional infrastructure necessary to support a scalable ecosystem connecting real-world economic activity with the emerging digital financial economy.

Importantly, these developments form part of TXTM’s broader corporate strategy as the Company advances its intended UPLIST TO A REGULATED EXCHANGE.

The Company’s institutional infrastructure initiatives, ongoing IFRS audit programme, international asset development and strategic relationships are designed to strengthen its institutional readiness and support the next stage of its capital-markets evolution.

The confirmation of ABSA’s inaugural pilot relationship represents an important advancement toward that objective.

THE INSTITUTIONAL CONNECTION WE HAVE BEEN WORKING TOWARD IS NOW ESTABLISHED AT THE PILOT LEVEL.

The Company is advancing from infrastructure development toward institutional implementation, with its intended uplist remaining a central corporate objective.

1.  ABSA × RIPPLE × TXTM: A SIGNIFICANT INSTITUTIONAL MILESTONE

ABSA has directly confirmed the Company’s Chairman’s participation as its first pilot client in its digital-asset custody onboarding process.

In correspondence to the Chairman, ABSA stated:

“Your participation is helping us test and refine not only the operational aspects of the service, but also the governance, risk and compliance requirements that a regulated bank must satisfy when supporting tokenised assets.”

This confirmation is significant.

ABSA is developing the operational, governance, risk and compliance framework required to support tokenised assets within a regulated banking environment.

The Company’s inaugural pilot participation places it within that process.

The Company has already developed and deployed its SVLT tokenisation infrastructure while pursuing the institutional relationships required to support its longer-term strategy.

The ABSA pilot provides an opportunity to bring these components together.

Separately, in October 2025, Ripple announced its partnership with ABSA to provide institutional digital-asset custody technology in South Africa.

OFFICIAL ANNOUNCEMENT — ABSA AND RIPPLE:

https://ripple.com/ripple-press/ripple-expands-global-custody-footprint-into-africa-with-absa-bank/

The emerging architecture can be illustrated as follows:

RIPPLE

ABSA’s publicly announced custody technology provider.

↓

ABSA

Institutional digital-asset custody infrastructure.

↓

TXTM / SVLT

Confirmed inaugural custody pilot participation.

↓

REAL-WORLD ASSETS

Existing tokenised assets and expanding asset pipeline.

This is a conceptual architecture and does not imply a direct commercial agreement between TXTM and Ripple.

The Company distinguishes its confirmed pilot participation with ABSA from any separate commercial relationship with Ripple.

Nevertheless, the strategic significance of this development is substantial. TXTM has been building its real-world asset infrastructure.
ABSA is developing institutional custody infrastructure.

The Company’s participation in ABSA’s inaugural pilot creates an opportunity to advance the connection between these two environments.

As TXTM progresses toward its intended uplist, this institutional relationship represents an important component of its broader effort to strengthen governance, operational infrastructure and institutional readiness.

THIS IS AN IMPORTANT ENABLING MILESTONE FOR THE ROADMAP.

2.  SVLT: CONNECTING TOKENISED REAL-WORLD ASSETS WITH INSTITUTIONAL INFRASTRUCTURE

SVLT represents an important component of the Company’s developing digital-asset infrastructure.

Deployed using an ERC-3643 permissioned token architecture, SVLT incorporates identity, compliance and administrative functionality intended to support institutional requirements.

Importantly, the Company’s agricultural seed initiative has already been tokenised.

The Company’s strategy is to connect qualifying real-world assets with a framework incorporating independent verification, tokenisation, governance and institutional custody.

TXTM’S RWA INFRASTRUCTURE

REAL-WORLD ASSETS

↓

INDEPENDENT VALUATION AND VERIFICATION

↓

SVLT TOKENISATION

↓

REGULATED INSTITUTIONAL CUSTODY

↓

COLLATERAL AND FINANCIAL UTILITY

The ABSA pilot represents progress toward the institutional custody component of this architecture. The Company is continuing the applicable operational, cybersecurity and onboarding processes.
The established SVLT infrastructure provides a foundation for expanding the model to other qualifying asset classes, including the Company’s pharmaceutical-related initiatives.

Future custody services and specific financing arrangements remain subject to their applicable commercial and regulatory requirements.

Importantly, the strategy does not begin or end with a single token.

SVLT is intended to support a broader ecosystem involving multiple qualifying asset classes, projects and jurisdictions.

3.  PROPRIETARY NANOTECHNOLOGY: DEVELOPING UNDERLYING ECONOMIC VALUE

A fundamental distinction in TXTM’s strategy is the integration of its proprietary nanotechnology and associated technological capabilities with its developing RWA infrastructure.

The Company is pursuing opportunities to apply these capabilities across qualifying commercial sectors, including agriculture and environmental applications.

The strategic objective is to develop measurable economic value that can subsequently qualify for digital representation and institutional financial applications.

THE COMPANY’S INTENDED MODEL:

PROPRIETARY TECHNOLOGY

↓

ECONOMIC ACTIVITY

↓

MEASURABLE ASSETS

↓

INDEPENDENT VERIFICATION

↓

TOKENISATION

↓

INSTITUTIONAL CONNECTIVITY

This creates the potential for an expanding asset pipeline.

As additional technologies, projects and commercial applications demonstrate independently supportable economic value, the Company intends to evaluate their eligibility for inclusion within its broader RWA ecosystem.

The Company recognises that technological potential does not automatically establish recognised balance-sheet value or tokenisation eligibility.

Commercialisation, appropriate accounting treatment, legal rights, independent valuation and verification remain essential.

The integration of proprietary technology with institutional digital-asset infrastructure represents an important element of TXTM’s long-term strategy.

4.  BRICS 2026, AfCFTA, CARICOM AND GRULAC: BUILDING INTERNATIONAL RELATIONSHIPS

The Company’s Chairman recently returned from India following his participation in BRICS 2026-related engagements.

These activities form part of the Company’s continuing efforts to establish international relationships and identify opportunities connecting real-world economic development with institutional financial infrastructure.

During his visit, the Chairman also met with His Excellency Jason Hall, Jamaica’s High Commissioner to India.

These engagements complement the Company’s broader relationship-building activities across Africa, BRICS economies, the Caribbean and Latin America.

The Company recognises the importance of the African Continental Free Trade Area (AfCFTA), the Caribbean Community (CARICOM) and the United Nations Group of Latin American and Caribbean Countries (GRULAC) within the wider economic and diplomatic landscape.

Together, these regions represent substantial opportunities involving agriculture, energy, natural resources, environmental infrastructure, technology and international trade.

The Company’s objective is to develop commercially viable relationships and identify qualifying projects across these markets.

These international engagements do not constitute commercial agreements with the regional organisations themselves.

Rather, they provide important context for the Company’s developing international strategy.

DIFFERENT MARKETS. DIFFERENT RESOURCES. ONE INCREASINGLY CONNECTED ECONOMIC LANDSCAPE.

5.  VENEZUELA: A CIRCULAR AGRICULTURAL AND ENERGY INFRASTRUCTURE OPPORTUNITY

The Company is advancing its Venezuela initiative, which involves a signed government pilot.

The proposed initiative introduces a circular agricultural infrastructure model connecting food production with potential renewable energy, resource recovery and environmental value creation.

The proposed process incorporates rice production, agricultural residue recovery, suitable biomass processing, biogas generation, renewable power and heat, and potential fertilizer and water recovery.

Subject to engineering and commercial feasibility, renewable electricity may also support future green-hydrogen production.

VENEZUELA: PROPOSED INTEGRATED VALUE CHAIN

01 — RICE PRODUCTION

02 — AGRICULTURAL RESIDUES

03 — BIOGAS GENERATION

04 — RENEWABLE POWER AND HEAT

05 — FERTILIZER AND RESOURCE RECOVERY

06 — POTENTIAL GREEN HYDROGEN

07 — POTENTIAL VERIFIED ENVIRONMENTAL ATTRIBUTES

Environmental attributes remain subject to eligible methodologies, independent verification and measurement, reporting and verification requirements.

The broader objective is to demonstrate how integrated agricultural infrastructure can create multiple measurable economic value streams.

Engineering feasibility, regulatory approvals, independent verification and project financing will determine which components can be commercially implemented.

Qualifying economic assets and contractual rights arising from such projects may subsequently be evaluated for inclusion within the Company’s RWA strategy.

6.  BRIGHTLY VENTURES AND B TERRA CORP: EXPANDING THE REAL-WORLD ASSET PIPELINE

The Company’s strategic relationships with Brightly Ventures and B Terra Corp represent additional elements of its developing ecosystem.

BRIGHTLY VENTURES

The Brightly relationship introduces opportunities involving environmental measurement, data infrastructure, verification and the development of qualifying environmental assets.

Measurement and independent verification are fundamental to establishing credible environmental economic value.

The Company intends to evaluate how these capabilities may complement its broader RWA and institutional infrastructure strategy.

THE INTERNATIONAL CARBON-MARKET CONNECTION

In April 2026, Xpansiv announced its planned offering of Brightly’s food-waste methane-reduction carbon credits through its CBL exchange.

The announcement identified an initial offering of approximately 250,000 ex-ante credits, with potential expansion to 500,000.

OFFICIAL ANNOUNCEMENT — BRIGHTLY AND XPANSIV:

https://www.xpansiv.com/news/xpansiv-to-launch-first-of-their-kind-food-waste-carbon-credits-from-brightly-on-cbl-exchange

This development is particularly relevant to the Company’s environmental and real-world asset strategy.

Separately, in October 2023, the Johannesburg Stock Exchange announced its collaboration with Xpansiv to establish an African voluntary carbon marketplace through JSE Ventures.

The marketplace provides access to international infrastructure for transactions involving qualifying carbon credits and renewable energy certificates.

OFFICIAL ANNOUNCEMENT — JSE AND XPANSIV:

https://www.jse.co.za/news/news/jse-collaborates-xpansiv-launch-voluntary-carbon-market-advance-south-africas-carbon

These independently announced developments demonstrate how environmental projects, carbon-market infrastructure and international financial markets are becoming increasingly connected.

They also provide relevant market context for TXTM’s broader RWA strategy and international ambitions.

Brightly’s announced relationship with Xpansiv and the JSE’s separate collaboration with Xpansiv do not constitute direct agreements between TXTM and those market operators.

Nevertheless, the developments illustrate a broader opportunity to connect independently verified environmental assets with established international market infrastructure.

B TERRA CORP

The Company’s strategic letter of intent with B Terra Corp introduces another potential component of its developing real-world asset pipeline.

Both relationships remain subject to their respective commercial milestones and definitive arrangements where applicable.

The Company’s objective is to develop a diversified ecosystem involving independently supportable assets, multiple commercial applications and appropriate institutional infrastructure.

7.  NATIVE NATIONS, INDIGENOUS ECONOMIES AND JURISDICTIONAL SOVEREIGNTY

South Africa’s Heritage Day, celebrated on September 24, provides an appropriate occasion to recognise the relationship between heritage, economic development and the stewardship of real-world resources.

The ancient Khoisan peoples of Southern Africa form an important part of this heritage.

The Company’s engagement with Native Nations introduces another dimension to its international strategy.

TXTM is exploring how modern digital infrastructure may interact with indigenous economic development while respecting the distinct legal, governmental and sovereign frameworks of participating communities.

Potential applications may include agriculture, natural resources, renewable energy, environmental stewardship, infrastructure, intellectual property and community enterprises.

Every jurisdiction and participating Native Nation has its own legal and governmental framework.

Any future initiative must respect applicable indigenous rights, land rights, governmental authority, legal requirements and community decision-making processes.

TECHNOLOGY MUST SERVE PEOPLE AND THEIR JURISDICTIONS — NOT REPLACE THEM.

This principle remains central to the Company’s approach.

8.  AN INCREASINGLY CONNECTED GLOBAL RWA ARCHITECTURE

The Company’s individual initiatives are designed to contribute to a broader strategic architecture.

TXTM’S DEVELOPING ECOSYSTEM

PROPRIETARY TECHNOLOGY

Nanotechnology and related opportunities for economic development.

REAL-WORLD ASSET DEVELOPMENT

Venezuela, Brightly, B Terra and other potential qualifying international projects.

SVLT INFRASTRUCTURE

Permissioned tokenisation, identity, compliance and asset administration.

INSTITUTIONAL CUSTODY

ABSA’s confirmed inaugural pilot participation and associated onboarding processes.

INTERNATIONAL CONNECTIVITY

Developing relationships across Africa, BRICS economies, the Caribbean, Latin America and Native Nations.

These initiatives involve different assets, jurisdictions, commercial arrangements and stages of development.

The Company’s objective is to connect qualifying opportunities through a common framework incorporating technology, governance, verification, compliance and institutional infrastructure.

The ABSA pilot represents an important milestone within that architecture.

Together, these initiatives are intended to strengthen the Company’s institutional foundation as it advances its proposed regulated-exchange uplist.

9.  THE NEXT PHASE: INSTITUTIONAL IMPLEMENTATION AND TXTM’S UPLIST STRATEGY

With the inaugural ABSA pilot relationship confirmed, the Company is advancing the next phase of its roadmap.

Its priorities include:

  • Progressing ABSA’s applicable custody onboarding, cybersecurity and operational requirements.
  • Advancing SVLT’s institutional governance, compliance and asset administration infrastructure.
  • Continuing the Company’s IFRS audit and financial reporting programme.
  • Developing qualifying assets and commercial opportunities through its existing strategic relationships.
  • Advancing the Company’s intended regulated-exchange uplist strategy and evaluating appropriate institutional financing pathways.

STRENGTHENING THE FINANCIAL FOUNDATION FOR UPLISTING

TXTM’s voluntary financial reporting programme represents another important component of its institutional-readiness strategy.

The Company has completed its 2022 and 2023 audits and is advancing its 2024 and 2025 IFRS audit programme.

Its existing Canadian engagement forms part of the next stage of its international financial reporting preparations.

This programme extends beyond the general independent-audit requirements applicable to qualifying OTCID issuers under the OTC Markets Alternative Reporting Standard.

In addition to improving international comparability, the programme provides an opportunity to establish the appropriate IFRS treatment of qualifying agricultural, pharmaceutical and other assets, including applicable foreign-currency translation effects.

The Company recognises that IFRS asset measurement and currency translation are distinct accounting considerations.

Their actual effects on reported assets, profit and shareholders’ equity will depend on the applicable accounting requirements and completed independent audits.

These initiatives are intended to support institutional due diligence, the Company’s planned regulated-exchange uplist and the continued development of long-term franchise value.

ADVANCING THE COMPANY’S REGULATED-EXCHANGE UPLIST

The Company’s intended uplist remains a central objective of its corporate strategy.

TXTM’s roadmap is designed to support its progression toward regulated-exchange listings and expanded participation in institutional capital markets.

The Company continues developing the financial reporting, corporate governance, institutional infrastructure and strategic relationships necessary to support that objective.

Its ongoing IFRS audit programme, proprietary technologies, SVLT infrastructure, developing real-world asset pipeline and institutional relationships represent complementary components of this strategy.

The objective is to establish a stronger institutional foundation, expand access to regulated capital markets and create opportunities for broader investor participation.

The Company will continue evaluating suitable exchange pathways, transaction structures and applicable regulatory requirements.

THE JSE: AN ADDITIONAL INTERNATIONAL CAPITAL-MARKETS OPPORTUNITY

In October 2022, the New York Stock Exchange and Johannesburg Stock Exchange announced an agreement concerning collaboration on dual listings.

The agreement also included exploration of opportunities involving ESG, exchange-traded funds and digital assets.

NYSE–JSE COLLABORATION:

https://www.businesswire.com/news/home/20221010005789/en/The-New-York-Stock-Exchange-and-The-Johannesburg-Stock-Exchange-Announce-Collaboration-on-Dual-Listings

This is particularly relevant to TXTM’s broader international strategy and its developing environmental and real-world asset initiatives.

In addition, the JSE’s revised listing requirements provide an expanded fast-track secondary-listing framework, including a 12-month minimum primary-listing period on an approved exchange.

OFFICIAL JSE FAST-TRACK SECONDARY-LISTING ANNOUNCEMENT:

https://www.jse.co.za/news/news/fsca-greenlights-jse-simplification-project

Following a successful qualifying primary uplist, TXTM intends to evaluate a potential secondary listing on the JSE.

Any such listing would remain subject to the Company’s primary listing venue, applicable eligibility requirements, regulatory approvals and completion of the necessary processes.

These exchange-level developments are not agreements with TXTM.

They nevertheless provide an established international regulatory and market framework relevant to the Company’s longer-term strategy.

THE ROADMAP TO UPLIST

INSTITUTIONAL READINESS

↓

STRONGER GOVERNANCE AND FINANCIAL REPORTING

↓

VERIFIED REAL-WORLD ECONOMIC VALUE

↓

REGULATED-EXCHANGE UPLIST

↓

LONG-TERM SHAREHOLDER VALUE

These are strategic objectives, not completed milestones or assured outcomes.

THE OBJECTIVE: INSTITUTIONAL READINESS, REGULATED MARKET ACCESS AND LONG-TERM SHAREHOLDER VALUE.

Institutional custody represents a key enabling component of the Company’s strategy.

The Company will continue evaluating institutional financing opportunities and intends to provide further shareholder updates as material milestones are achieved.

Any proposed uplist remains subject to applicable exchange listing standards, financial and governance requirements, regulatory approvals and completion of the relevant processes.

FROM INFRASTRUCTURE DEVELOPMENT TO INSTITUTIONAL IMPLEMENTATION. FROM INSTITUTIONAL IMPLEMENTATION TOWARD A REGULATED-EXCHANGE UPLIST. THE ROADMAP IS MOVING.

10.   MESSAGE FROM THE CHAIRMAN

Dr. Ahmed Jamaloodeen, Chairman of ProText Mobility, Inc., stated:

“Our shareholders have remained with us as we have pursued a strategy extending beyond any single technology, asset class, financial institution or jurisdiction.

“We recognised early that meaningful real-world asset tokenisation would require more than blockchain technology.

“It would require real assets, independently supportable valuations, governance, regulatory compliance, institutional relationships and appropriate custody infrastructure.

“ABSA’s confirmation of our inaugural pilot participation represents an important milestone in that journey.

“One of the key institutional relationships we have been working toward is now established at the pilot level.

“This enables us to advance the next phase of our strategy, connecting proprietary technology, real-world economic development and institutional financial infrastructure.

“Our intended uplist remains a central objective of our corporate strategy.

“Our IFRS audit programme, proprietary technology, international initiatives, SVLT infrastructure and ABSA custody pilot are components of this broader strategy.

“We are voluntarily investing in international financial reporting standards and developing the institutional foundations necessary to support our future.

“Our objective is to establish an institutional foundation capable of supporting our intended uplist and creating sustainable long-term value for our shareholders.

“The roadmap is not simply about tokenisation. It is about strengthening our institutional infrastructure, developing independently supportable economic value and advancing the Company’s capital-markets strategy.

“Our focus remains on governance, compliance, verification, custody, jurisdiction, scalability and execution.

“We thank our shareholders for their continued patience, confidence and support.

“THE ROADMAP IS MOVING.”

11.   HERITAGE, RESONANCE AND OUR SHARED FUTURE

The Company’s international vision recognises that meaningful economic development must respect the people, communities, cultures and jurisdictions that create and sustain real-world value.

As South Africa celebrates its heritage, TXTM recognises the importance of building economic relationships across cultures and borders.

The Company’s guiding philosophy remains: 432 Hz

RESONANCE → ALIGNMENT → EXECUTION

SIMUNYE

WE ARE ONE.

Different countries. Different cultures. Different jurisdictions. Different assets. Different technologies.

ONE INCREASINGLY CONNECTED VISION.

From heritage to real-world value.

From real-world value to institutional infrastructure.

From institutional infrastructure toward a regulated-exchange uplist. From institutional infrastructure to the digital economy.

THE ROADMAP IS MOVING.

ABOUT PROTEXT MOBILITY, INC.

ProText Mobility, Inc. is pursuing a strategy involving proprietary technology, real-world assets, digital tokenisation and institutional financial infrastructure.

The Company’s roadmap incorporates international relationship development and opportunities to connect qualifying economic assets with compliant digital financial infrastructure.

The Company is advancing an intended regulated-exchange uplist strategy, supported by its ongoing financial reporting programme, institutional infrastructure development and broader real-world asset initiatives.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including statements concerning the Company’s business strategy, proposed projects, tokenisation infrastructure, commercial relationships, potential financing arrangements, regulatory processes, intended uplist and anticipated developments.

These statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied.

Pilot participation does not guarantee commercial custody services, institutional financing, asset eligibility, liquidity, exchange-listing approval or future revenue.

Proposed transactions and initiatives may require additional agreements, independent verification, regulatory approvals and financing.

The Company’s intended uplist is subject to applicable exchange-listing standards, financial and corporate governance requirements, regulatory processes and other relevant conditions.

The possibility of a subsequent JSE listing would introduce further eligibility requirements and approvals.

No assurance can be given that a proposed uplist will be completed or that any particular exchange will approve the Company’s securities for listing.

The Company undertakes no obligation to update forward-looking statements except as required by applicable law.

INVESTOR RELATIONS & MEDIA CONTACT

Mr. Dylon Du Plooy
Chief Executive Officer Email: dylon@rsammd.co.za
X: https://x.com/MrDylonDuPlooy
Executive profile: https://protxtm.com/mr-d-du-plooy-ceo/

Dr. Ahmed Jamaloodeen (Dr. J)
President & Chairman Email: exportintl@aol.com
X: https://x.com/Dr_Jamaloodeen
Executive profile: https://protxtm.com/dr-a-jamaloodeen-md-chairman/

Company Website: https://protxtm.com/
Investor Relations: https://protxtm.com/investor-relations/

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/85847555-2fbd-44b0-894b-325fe40c75ce

Sean McGarvy headshot

Sean McGarvy
Sean McGarvy

CINCINNATI, Sept. 28, 2026 (GLOBE NEWSWIRE) — The E.W. Scripps Company (NASDAQ: SSP) has promoted veteran news leader Sean McGarvy to head of news, effective Oct. 5.   

McGarvy will lead news and content strategy and oversee news standards for Scripps News Group, bringing Scripps’ local newsrooms, digital operations and Scripps News, the company’s national streaming news network, closer together under a unified, consumer-focused strategy. In this role, he will drive efforts to extend the reach and impact of Scripps’ journalism across broadcast, streaming and digital platforms as the company continues transforming how it delivers trusted journalism and builds stronger community connections.  

McGarvy will report to Dean Littleton, who was promoted to president of media in July. 

“Scripps’ transformation is about evolving our organization to serve audiences and communities in new ways,” Littleton said. “Our journalism is central to that work, and Sean brings the news judgment, operational discipline and audience focus needed to help align our local newsrooms, digital operations and Scripps News around the needs of American news consumers. His leadership will help us move trusted journalism faster across platforms while strengthening the connection between our reporting and the communities we serve.”   

Most recently, McGarvy served as Scripps’ senior director of digital news operations, leading strategy and audience growth across Scripps News Group’s digital platforms, including YouTube and Meta. He has helped expand the reach and impact of the company’s journalism through audience-driven news strategies and a coordinated approach to digital publishing and streaming news. Previously, as senior director of local news strategy, he worked with Scripps’ local TV markets to deepen community connection and strengthen collaboration across Scripps News Group.  

Earlier in his Scripps career, McGarvy was news director at WEWS, Scripps’ ABC affiliate in Cleveland, and assistant news director at KMGH, Scripps’ ABC affiliate in Denver. His career spans almost 30 years in newsrooms across the country, including managing editor and assignment manager roles at local TV stations and Fox News Channel. His work has been recognized with seven Edward R. Murrow Awards and 10 regional Emmy Awards.  

McGarvy holds a Bachelor of Arts degree in broadcast journalism from the University of Missouri in Columbia.  

Media contact: Becca McCarter, The E.W. Scripps Company, (513) 410-2425, rebecca.mccarter@scripps.com

About Scripps
The E.W. Scripps Company (NASDAQ: SSP) is a diversified media company focused on creating connection. As one of the nation’s largest local TV broadcasters, Scripps serves communities with quality, objective local journalism and operates a portfolio of about 60 stations in 40 markets. Scripps reaches households across the U.S. with national news outlet Scripps News and popular entertainment brands ION, Bounce, Grit, ION Mystery, ION Plus and Laff. Scripps is one of the nation’s largest holders of broadcast spectrum. Scripps Sports serves professional and college sports leagues, conferences and teams with local market depth and national broadcast reach of up to 100% of TV households. Founded in 1878, Scripps is the steward of the Scripps National Spelling Bee, and its longtime motto is: “Give light and the people will find their own way.”

Scripps in the news            Scripps press releases

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5c80b07d-fd26-4481-8163-04d5b3bae28b

  • Financial Highlights
    • Cash and cash equivalents totaled €113.8 million as of June 30, 2026; expected to fund the Company beyond the end of 2028
    • €21.1 million in revenues as of June 30, 2026, including €21.0 million in royalties generated under the Ipsen agreement
  • Key Highlights
    • PBC: Ipsen doubled its peak annual global sales target for Iqirvo® in PBC to €1 billion, underscoring the value creation potential of GENFIT’s licensing agreement
    • MASH: Medicare coverage secured in August 2026 in the United States for NASHnext®, the Labcorp-commercialized test based on GENFIT’s NIS™ technology; estimated U.S. peak sales of products based on GENFIT’s NIS™ technology could exceed $1.5 billion by 2033 (IQVIA)
    • ACLF: Clinical-stage pipeline re-focused on the planned initiation of two Phase 2 clinical trials, of nangibotide and nitazoxanide, before year-end
    • CCA: Continued advancement of GNS561 in combination therapy, including expansion of the Phase 1b study into additional cohorts following encouraging preliminary data; preparation for a Phase 2 trial expected to commence before year-end

Lille (France), Cambridge (Massachusetts, United States); September 28, 2026 – GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its first half 2026 financial results and provided a corporate update.

Pascal Prigent, CEO of GENFIT, commented: “We are pleased with the progress across our businesses and believe we now have a strong platform to build upon. Iqirvo® continues to perform above expectations, with royalty revenue more than tripling in the first half of 2026 compared with the same period last year. This momentum could be further supported by the very encouraging ELSPIRE Phase 3 results and is reflected in Ipsen’s recent increase in its peak-sales guidance to €1 billion. At the same time, our MASH diagnostics business is emerging as a potentially significant contributor to future revenues, as the key challenge in this large market is shifting from treatment availability to patient identification and monitoring. Finally, we are starting three distinct Phase 2 studies, with readouts expected next year, each addressing a challenging condition where we believe our programs have the potential to make a meaningful difference.”

I. Financial update

Cash and cash equivalents

As of June 30, 2026, the Company’s cash and cash equivalents amounted to €113.8 million compared with €101.1 million as of December 31, 2025.

In 2026, cash consumption was primarily driven by research and development activities across our Acute-on-Chronic Liver Failure (ACLF) franchise programs, notably NTZ/G1090N, SRT-015, CLM-022 and VS-02 HE, as well as our GNS561 program in cholangiocarcinoma (CCA). This cash consumption was offset by two significant cash inflows during the first half of 2026: (i) the second €30.0 million tranche received under the royalty financing agreement and (ii) the receipt of the first commercial milestone payment of €17.0 million from Ipsen (USD$20.0 million), which had already accrued for in 2025 and received in 2026..

We expect that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements beyond the end of 2028, enabling the Company to further develop its R&D pipeline and support general corporate purposes. This is based on current assumptions and programs and does not include exceptional events. This estimation assumes (i) our expectation to receive significant future commercial milestone revenue pursuant to the Ipsen Agreement and Ipsen meeting its sales-based thresholds and (ii) drawing down the third and final, optional installment under the Royalty Financing agreement.

Financial highlights

The table below presents the condensed Consolidated Statement of Operations under International Financial Reporting Standards (IFRS) for the first half of 2026, with comparative figures for the first half of 2025.

  Half-year ended
(in € thousands, except earnings per share data) 2025/06/30 2026/06/30
Revenues and other income    
Revenue 33,488 21,073
Other income 2,182 3,960
Revenues and other income 35,670 25,033
Operating expenses and other operating income (expenses)    
Research and development expenses (25,117) (24,927)
General and administrative expenses (9,971) (8,328)
Marketing and market access expenses (392) (15)
Other operating expenses (115) (487)
Operating income (loss) 76 (8,724)
Financial income 1,850 1,463
Financial expenses (12,027) (18,854)
Financial profit (loss) (10,178) (17,392)
Net profit (loss) before tax (10,102) (26,116)
Income tax benefit (expense) 146 (5)
Net profit (loss) (9,956) (26,120)
Basic and diluted earnings (loss) per share    
Basic earnings (loss) per share (€/share) (0.20) (0.52)
Diluted earnings (loss) per share (€/share) (0.20) (0.52)

The Group’s condensed statement of financial position, condensed statement of net income and condensed statement of cash flows, prepared in accordance with IFRS accounting standards, are presented in the Appendix of this document.

Detailed information on the condensed consolidated financial statements, together with the statutory auditors’ review report, is provided in the 2026 Half-Year Business and Financial Report, available in the “Investors” section of GENFIT’s website.

We encourage investors to take into consideration all the information presented in our 2025 Universal Registration Document filed under D.26-0221 with the French Autorité des Marchés Financiers (AMF) on April 3, 2026 and the 2026 Half-Year Business and Financial Report before deciding to invest in Company shares; these documents are available on GENFIT’s website: www.genfit.com and on the website of the AMF (www.amf-france.org). This includes, in particular, the risk factors described in section 2 of the 2025 Universal Registration Document, as well as the update provided in section 2.5 of the 2026 Half-Year Business and Financial Report, of which the realization may have (or has had in some cases) material adverse effect on the Group and its activity, financial situation, results, development or perspectives, and which are of importance in the investment decision-making process.

Financial highlight comments

Revenue

Revenue Half-year ended
(In € thousands) 30/06/2025 30/06/2026
Royalty revenue 6,871 20,975
Milestone revenue 26,556 0
Other revenue 61 98
TOTAL 33,488 21,073

Royalty revenue
Virtually all royalty revenue is derived from worldwide sales of Ipsen’s Iqirvo1 (elafibranor) under the Ipsen Agreement. These are utilized to repay the Group’s Royalty Financing agreement.

Milestone revenue
On May 20, 2025, GENFIT announced that Ipsen’s Iqirvo (elafibranor) was granted pricing and reimbursement in Italy for PBC, the third major European country to do so in addition to the UK and Germany. This third approval triggered a new milestone payment of €26.5 million under GENFIT’s Licensing and Collaboration Agreement with Ipsen, due upon pricing and reimbursement of Iqirvo (elafibranor) in three major European markets.

When comparing total revenues year on year, the timing of milestone payments should be kept in mind: revenues in the first half of 2025 included a milestone payment, whereas no milestone revenue was recognized in the first half of 2026. Additional milestone payments may, however, be recognized in the future.

Other income

Other income Half-year ended
(in € thousands) 06/30/2025 06/30/2026
CIR tax credit 2,030 3,091
Other operating income (including exchange gains on trade payables and receivables) 135 854
Government grants and subsidies 17 15
TOTAL 2,182 3,960

The increase in the CIR research tax credit compared to the prior period was primarily driven by an increase in eligible research and development expenses.

Operating expenses

Operating expenses amounted to €33.8 million in 2026, compared with €35.6 million in 2025, and comprised research and development expenses, general and administrative expenses, marketing and pre-commercialization expenses, and other operating income and expenses.

Research and development expenses decreased in 2026 compared with the prior period, primarily as a result of the discontinuation of the VS-01-ACLF program in 2025. This decrease was partially offset by the advancement of development activities across the Group’s other priority programs, notably nitazoxanide (NTZ), VS-02-HE, GNS561 and VS-01-UCD.

General and administrative expenses decreased in 2026 compared with the prior period, primarily due to the non-recurrence of costs related to the liquidation of Versantis recognized in 2025, as well as cost savings resulting from the Company’s delisting from the Nasdaq.

Financial results

The Group recorded a financial loss of €17.4 million in the first half of 2026, compared with a financial loss of €10.2 million in the first half of 2025.

Financial expenses increased in 2026 compared with the prior period, primarily due to changes in the fair value of the royalty financing liability recognized in profit or loss.

Net loss

The first half of 2026 resulted in a net loss of €26.1 million, compared with a net loss of €10.0 million in the first half of 2025.

II. Business update

Two emerging revenue streams

  • Elafibranor in cholestatic liver diseases

PBC – On July 30, 2026 Ipsen reported its Iqirvo (elafibranor) sales results for the first half of 2026. Ipsen upgraded its peak sales estimates from €500 million to €1 billion in Primary Biliary Cholangitis (PBC). This revision followed Ipsen’s announcement on July 13, 2026, that the primary endpoint of alkaline phosphatase (ALP) normalization had been achieved in 85% of patients treated with Iqirvo (elafibranor), compared with 23% of patients receiving placebo, in the Phase 3 ELSPIRE study. This revision is also explained by accelerated sales growth in the US driven by a higher number of patients, and strong launches across European countries. Iqirvo’s net sales for the first six months of 2026 amounted to €173 million2. This momentum also allowed GENFIT to activate, in January 2026, an additional €30 million tranche under GENFIT’s Royalty Financing agreement with HCRx, enhancing financial flexibility without shareholder dilution.
PSC – Beyond PBC, Ipsen announced the initiation of the Phase 3 ELASCOPE study evaluating elafibranor in Primary Sclerosing Cholangitis (PSC) in early 2026. The PSC market opportunity is estimated to be comparable in size to the second‑line PBC market. Subject to successful development and regulatory approval of elafibranor in this indication, GENFIT would be eligible to receive additional milestone payments as well as incremental double‑digit royalties. Data readout from the Phase 3 trial is expected around 2031.

  • NISTM Technology in MASH

Program status – In August 2026, Medicare reimbursement of Labcorp’s NASHnext® test (based on GENFIT’s NIS™ technology) became effective under the Clinical Laboratory Fee Schedule for patients meeting coverage criteria. GENFIT believes broader reimbursement by private payers, if obtained, could support accelerated adoption of its technology over time. Further market expansion could also be supported by a potential future in vitro (IVD) launch, which may facilitate deployment across a wider range of healthcare settings.
Highlights on U.S. Market Potential – Based on intention-to-diagnose data collected across key specialties, increasing disease prevalence, and a staged commercialization strategy spanning Laboratory Developed Tests (LDTs) and In Vitro Diagnostics (IVDs), IQVIA estimates U.S. peak sales of products using GENFIT’s technology could exceed $1.5 billion by 2033, with annual testing volume in the U.S. reaching more than 7 million tests.3
Beyond the United States – In Europe and Asia, GENFIT expects its IVD strategy to play a key role in the future commercialization of its NIS™ technology. Supported by the anticipated expansion of the MASH therapeutic market and the broader accessibility enabled by IVD products, international markets could represent a meaningful additional revenue opportunity over time.

R&D pipeline

  • Clinical stage: Three programs entering Phase 2 clinical development in the second half of 2026

Two assets in Acute on-Chronic Liver Failure (ACLF)
Nangibotide – In summer 2026, GENFIT acquired nangibotide, a differentiated late-stage asset, reinforcing the Company’s portfolio of innovative therapies addressing high unmet medical needs. The investigation in Phase 2 is supported by a robust scientific and clinical foundation around the TREM-1 pathway and the asset’s profile:

  • Strong knowledge of nangibotide’s biological pathway
  • Multiple efficacy signals already observed with nangibotide in post-hoc analyses of three Phase 2 clinical trials in septic shock and COVID-19 subjects, including a statistically significant reduction in mortality in severe COVID-19 and significant improvements in SOFA score from baseline in septic shock
  • Overall favorable safety and tolerability profile demonstrated across four clinical trials, with more than 400 subjects exposed to nangibotide, and no meaningful differences versus placebo in safety outcomes

Nangibotide is expected to enter a Phase 2 study in ACLF in the fourth quarter of 2026, with data readout targeted in 2027.
Nitazoxanide (NTZ) – Positive Phase 1 data reported in early 2026 confirmed the favorable safety profile of NTZ and demonstrated multi‑modal biological activity, supporting its continued clinical development across the ACLF disease continuum. In March 2026, NTZ was granted Orphan Drug Designation for the treatment of ACLF. A proof‑of‑concept study was initiated in the third quarter of 2026, with data expected in 2027.

One asset in oncology
GNS561 – Encouraging preliminary data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated CCA were disclosed in December 2025 and June 2026. This Phase 1b dose escalation is progressing as planned, with additional data anticipated in the second half of 2026, following study expansion into additional cohorts supported by preliminary signals. The Phase 2 initiation is on track for launch in the second semester of 2026. Phase 2 data readout is targeted in 2027.

  • Research stage: multiple targets in ACLF and oncology

ACLF – GENFIT’s strategy for the treatment of ACLF is concentrated around its two most advanced assets, nangibotide and NTZ, both entering Phase 2 clinical investigations in 2026, as well as the potential of extracellular vesicle-based approaches. This focus is underpinned by robust body of evidence generated through internal preclinical research, external datasets, translational analyses, and ongoing interactions with leading international hepatology and critical care experts. GENFIT is thus directing its capital and development resources towards the programs with the strongest translational rationale and clinical potential, and has discontinued the development of SRT-015 and CLM-022 programs. The evaluation of the VS-02-HE program remains ongoing, alongside continued exploration of additional mechanisms of action relevant to ACLF. Further updates will be provided as these programs mature and progress toward clinical development.

Oncology – Following the encouraging preliminary results observed with GNS561 in combination with a MEK inhibitor in cholangiocarcinoma (CCA), further supporting the therapeutic potential of autophagy inhibition, GENFIT has initiated research activities to explore this approach in additional oncology indications and in combination with other therapeutic agents. Further details will be provided as and when these programs advance into clinical development.

Corporate governance updates

In February 2026, Mr. John BROZEK replaced Ms. Florence SÉJOURNÉ as permanent representative of Biotech Avenir SAS on the Company’s Board of Directors.

Extra-financial performance

In May 2026 GENFIT published its annual Extra-Financial Performance Report (fiscal year 2025), highlighting its latest initiatives and providing insights on the evolution of key performance indicators. In terms of recognition, GENFIT maintained its “Prime status” with ISS ESG and gold medal awarded by Ethifinance in recognition of its ESG performance. GENFIT is also a Certified B Corporation since 2025.

  Half-year Consolidated Financial Results at June 30, 2026  
   

The Condensed Consolidated Statements of Financial Position, Statements of Operations and Statements of Cash Flow of the Group were prepared in accordance with the IFRS.

The limited review procedures on the condensed consolidated financial statements have been performed. The half-year consolidated financial statements for the period ended June 30, 2026 were approved by the Board of Directors on September 28, 2026.

The condensed consolidated financial statements as well as the notes to the consolidated financial statements for the period ended June 30, 2026 and the statutory auditor’s report on the consolidated financial statements are included in the Half Year Business and Financial Report at June 30, 2026 available on the “Investors” page of the GENFIT website.

All financial information (unless indicated otherwise) is presented in thousands of euros (€).

Condensed Consolidated Statement of Financial Position

Assets

  As of
(in € thousands) 2025/12/31 2026/06/30
Current assets    
Cash and cash equivalents 101,093 113,822
Current trade and other receivables 40,328 24,776
Other current assets 2,857 2,813
Inventories 4 4
Total – Current assets 144,282 141,416
Non-current assets    
Intangible assets 4,155 2,102
Property, plant and equipment 7,100 6,674
Other non-current financial assets 3,503 3,375
Deferred tax assets 0 0
Total – Non-current assets 14,759 12,151
Total – Assets 159,041 153,567

Shareholders’ equity and liabilities

  As of
(in € thousands) 2025/12/31 2026/06/30
Current liabilities    
Current convertible loans 0 0
Other current loans and borrowings 2,025 2,020
Current trade and other payables 26,392 19,192
Current provisions 2,958 2,052
Other current tax liabilities 0 0
Total – Current liabilities 72,312 89,251
Non-current liabilities    
Other non-current loans and borrowings 3,546 2,535
Non-current employee benefits 1,475 1,580
Deferred tax liabilities 0 0
Total – Non-current liabilities 109,265 112,852
Shareholders’ equity    
Share capital 12,509 12,524
Share premium 440,303 440,930
Retained earnings (accumulated deficit) (389,813) (475,908)
Currency translation adjustment 433 38
Net profit (loss) (85,968) (26,120)
Total – Shareholders’ equity (22,536) (48,536)
Total – Shareholders’ equity & liabilities 159,041 153,567
     

Condensed Consolidated Statement of Operations

  Half-year ended
(in € thousands, except earnings per share data) 2025/06/30 2026/06/30
Revenues and other income    
Revenue 33,488 21,073
Other income 2,182 3,960
Revenues and other income 35,670 25,033
Operating expenses and other operating income (expenses)    
Research and development expenses (25,117) (24,927)
General and administrative expenses (9,971) (8,328)
Marketing and market access expenses (392) (15)
Other operating expenses (115) (487)
Operating income (loss) 76 (8,724)
Financial income 1,850 1,463
Financial expenses (12,027) (18,854)
Financial profit (loss) (10,178) (17,392)
Net profit (loss) before tax (10,102) (26,116)
Income tax benefit (expense) 146 (5)
Net profit (loss) (9,956) (26,120)
Basic and diluted earnings (loss) per share    
Basic earnings (loss) per share (€/share) (0.20) (0.52)
Diluted earnings (loss) per share (€/share) (0.20) (0.52)

Condensed Statement of Cash Flows

  Half-year ended Half-year ended
(in € thousands) 2025/06/30 2026/06/30
Cash flows from operating activities    
+ Net profit (loss) (9,956) (26,118)
Reconciliation of net loss to net cash used in operating activities    
Adjustments for:    
+ Depreciation and amortization on tangible and intangible assets 897 943
+ Impairment and provisions 193 2,238
+ Expenses related to share-based compensation 242 485
– Loss (gain) on disposal of property, plant and equipment (12) 0
+ Net finance expenses (revenue) 6,324 17,940
+ Income tax expense (benefit) (146) 5
+ Other non-cash items 590 (11)
Operating cash flows before change in working capital (1,868) (4,518)
Decrease (increase) in trade receivables and other assets (37,840) 14,190
(Decrease) increase in trade payables and other liabilities 9,606 (6,714)
Change in working capital (28,234) 7,476
Income tax paid 0 0
Net cash flows provided by (used in) in operating activities (30,102) 2,958
Cash flows from investment activities    
– Acquisition of other intangible assets (2,034) (6)
– Acquisition of property, plant and equipment (1,054) (537)
+ Proceeds from disposal of / reimbursement of property, plant and equipment 39 0
– Acquisition of financial instruments (170) (37)
+ Proceeds from sale of financial instruments 0 22
Net cash flows provided by (used in ) investment activities (3,219) (557)
Cash flows from financing activities    
+ Proceeds from issue of share capital (net) 17 154
+ Proceeds from new loans and borrowings 130,020 30,000
– Repayments of loans and borrowings (62,105) (431)
– Repayments of royalty financing liability (4,492) (18,723)
– Payments of debt issuance costs (3,363) (375)
– Payments on lease debts (555) (586)
– Financial interests paid (including finance lease) (530) (34)
+ Financial interests received 295 429
Net cash flows provided by (used in ) financing activities 59,287 10,435
Increase (decrease) in cash and cash equivalents 25,966 12,835
Cash and cash equivalents at the beginning of the period 81,788 101,093
Effects of exchange rate changes on cash (243) (106)
Cash and cash equivalents at the end of the period 107,511 113,822

ABOUT GENFIT

GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow. GENFIT’s expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for second-line treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries.4 Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis). GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT) and joined the CAC Mid 60 and SBF 120 indices on September 18, 2026. In 2021, Ipsen became one of GENFIT’s largest shareholders, acquiring an 8% stake in the Company’s capital. www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including, but not limited to, statements relating to the sales trajectory and future commercial performance of Iqirvo® in PBC, elafibranor’s ability to be successfully developed and subsequently approved in PSC, and the size of the market opportunity that PSC may represent; the possibility of receiving future milestone payments and royalties under its license agreement with Ipsen; relating to the future development of its NIS™ technologies in MASH diagnosis and the size of the market opportunity that MASH may represent, including the development and regulatory approval of new MASH therapies and their commercial adoption and rollout; the adoption of NASHnext® as a diagnostic test to identify patients with at-risk MASH and the size of this patient population; reimbursement of the test by private payors; the Company’s ability to establish partnerships with major pharmaceutical companies commercializing such therapies; its ability to develop an IVD (In Vitro Diagnostic) version of a diagnostic test based on these technologies; and the possibility of receiving future revenues under its license agreement with Labcorp; relating to the future development of the GNS561/trametinib combination and the anticipated timelines for obtaining additional Phase 1b results, initiating Phase 2 of the ongoing Phase 1b/2 clinical trial in CCA, and obtaining the results thereof, as well as the potential of GNS561 in combination with other treatments and/or in other cancer indications; relating to the future development of NTZ/G1090N in ACLF, including the significance and implications of NTZ’s FDA Orphan Drug Designation (ODD), the initiation of a Phase 2 clinical trial under the NTZ/G1090N program, and the anticipated timelines for obtaining its results; relating to the future development of nangibotide, including the potential relevance on future clinical investigations of efficacy signals and safety data observed in prior clinical studies conducted in other indications, as well as the Company’s ability to initiate a Phase 2 program with this drug candidate in this indication and the anticipated timelines for such initiation and the availability of results; relating to the objectives of its portfolio management strategy; and, more generally, forward-looking statements regarding its financial position, the expected progress of its research and development programs, and their potential therapeutic benefits in the indications for which they are intended. The use of certain words, such as “believe”, “potential”, “expect”, “target”, “may”, “will”, “should”, “could”, “if” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to non-clinical and pre-clinical programs, reproducibility of preclinical results, the translation of animal model data to human biology, in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Risk Factors and Internal Control” of the Company’s 2025 Universal Registration Document filed on April 3, 2026 (no. 26-0221) with the Autorité des marchés financiers (“AMF”), which is available on GENFIT’s website (www.genfit.fr) and the AMF’s website (www.amf.org), and those discussed in reports filed with the AMF or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACTS

GENFIT | Investors
Jean-Christophe Marcoux – Chief Corporate Affairs Officer | Tel : + 33 3 20 16 40 00 | jean-christophe.marcoux@genfit.com

Kevin Gardner – Life Science Advisors | kgardner@lifesciadvisors.com

GENFIT | Media
Bruno ARABIAN – Agence Maarc | Tel : 06 87 88 47 26 | bruno.arabian@maarc.fr

Stephanie BOYER | Tel : + 33 3 20 16 40 00 | stephanie.boyer@genfit.com

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos – FRANCE | +333 2016 4000 | www.genfit.com


1 Iqirvo® is a registered trademark of GENFIT SA

2 https://www.ipsen.com/wp-content/uploads/2026/07/Ipsen-PR_HY-2026_30072026.pdf

3 Regulatory authorization through the applicable local approval process is required for IVD products and has not yet been obtained.

4 Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo®

Attachment

HONG KONG, Sept. 28, 2026 (GLOBE NEWSWIRE) — Masonglory Limited (the “Company”) (Nasdaq: MSGY), a subcontractor providing wet trades services and other ancillary services in Hong Kong, today announced that on September 25, 2026, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with four investors (collectively, the “Purchasers”), pursuant to which the Purchasers agreed to purchase from the Company, in a private placement (the “Private Placement”), an aggregate of 667,000 Class A ordinary shares of the Company, par value US$0.0008 each (the “Class A Ordinary Shares”), at a purchase price of US$1.50 per share, for aggregate gross proceeds to the Company of approximately US$1.0 million (US$1,000,500), before deducting offering expenses.

In addition, for no additional consideration, each Purchaser will receive at the closing of the Private Placement a Series A warrant to purchase up to 166,750 Class A Ordinary Shares at an exercise price of US$1.30 per share and a Series B warrant to purchase up to 166,750 Class A Ordinary Shares at an exercise price of US$1.10 per share (collectively, the “Warrants”). The Warrants are exercisable from the date of issuance and have a term of two years from the date of issuance.

The Company expects to complete the closing of the transactions contemplated by the Securities Purchase Agreement as soon as practicable, subject to the satisfaction of customary closing conditions, and to issue the Class A Ordinary Shares and the Warrants to the Purchasers at the closing.

The Company intends to use the net proceeds from the Private Placement to fund the continued acquisition of equity interests in Beta Beteiligungs und Besitz GmbH, a private limited liability company organized under the laws of the Republic of Austria (the “Target”), which is engaged in the trading and distribution of construction materials, principally bathtubs, hot tubs and swim spas, in Continental Europe. As previously announced on August 13, 2026, the Company entered into a share swap agreement on August 12, 2026 to acquire a 20% equity interest in the Target. The specific percentage of additional equity interests in the Target to be acquired and the consideration therefor are still under negotiation between the Company and the Target, and no definitive agreement in respect thereof has been entered into as of the date of this press release. The Company will make further announcement(s) in respect of the foregoing as and when appropriate.

The Class A Ordinary Shares to be issued in the Private Placement, the Warrants and the Class A Ordinary Shares issuable upon exercise of the Warrants have been and will be issued and sold in an offshore transaction without registration under the Securities Act of 1933, as amended, in reliance on applicable exemptions from registration, and will constitute “restricted securities”. Each Purchaser has represented to the Company that it is not affiliated with the Company or any of its directors or officers. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Masonglory Limited

Founded in 2018 in Hong Kong, Masonglory Limited is a subcontractor providing wet trades services and other ancillary services to property developers and Hong Kong government. As a registered specialist trade contractor (plastering-group 2) since 2020, the Company provides customers with comprehensive wet trades works solutions, which principally include: (i) plastering on floors, ceilings, and walls; (ii) tile laying on internal and external walls and floors; (iii) brick laying; (iv) floor screeding; and (v) marble works. For more information, please visit: https://www.masontech.com.hk/; https://ir.masontech.com.hk/

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “aim”, “anticipate”, “believe”, “estimate”, “expect”, “going forward”, “intend”, “may”, “plan”, “potential”, “predict”, “propose”, “seek”, “should”, “will”, “would” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

For more information, please contact:

Masonglory Limited

Investor Relations Department

Email: services@wealthfsllc.com

HONG KONG, Sept. 28, 2026 (GLOBE NEWSWIRE) — Masonglory Limited (the “Company”) (Nasdaq: MSGY), a subcontractor providing wet trades services and other ancillary services in Hong Kong, today announced that on September 25, 2026, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with four investors (collectively, the “Purchasers”), pursuant to which the Purchasers agreed to purchase from the Company, in a private placement (the “Private Placement”), an aggregate of 667,000 Class A ordinary shares of the Company, par value US$0.0008 each (the “Class A Ordinary Shares”), at a purchase price of US$1.50 per share, for aggregate gross proceeds to the Company of approximately US$1.0 million (US$1,000,500), before deducting offering expenses.

In addition, for no additional consideration, each Purchaser will receive at the closing of the Private Placement a Series A warrant to purchase up to 166,750 Class A Ordinary Shares at an exercise price of US$1.30 per share and a Series B warrant to purchase up to 166,750 Class A Ordinary Shares at an exercise price of US$1.10 per share (collectively, the “Warrants”). The Warrants are exercisable from the date of issuance and have a term of two years from the date of issuance.

The Company expects to complete the closing of the transactions contemplated by the Securities Purchase Agreement as soon as practicable, subject to the satisfaction of customary closing conditions, and to issue the Class A Ordinary Shares and the Warrants to the Purchasers at the closing.

The Company intends to use the net proceeds from the Private Placement to fund the continued acquisition of equity interests in Beta Beteiligungs und Besitz GmbH, a private limited liability company organized under the laws of the Republic of Austria (the “Target”), which is engaged in the trading and distribution of construction materials, principally bathtubs, hot tubs and swim spas, in Continental Europe. As previously announced on August 13, 2026, the Company entered into a share swap agreement on August 12, 2026 to acquire a 20% equity interest in the Target. The specific percentage of additional equity interests in the Target to be acquired and the consideration therefor are still under negotiation between the Company and the Target, and no definitive agreement in respect thereof has been entered into as of the date of this press release. The Company will make further announcement(s) in respect of the foregoing as and when appropriate.

The Class A Ordinary Shares to be issued in the Private Placement, the Warrants and the Class A Ordinary Shares issuable upon exercise of the Warrants have been and will be issued and sold in an offshore transaction without registration under the Securities Act of 1933, as amended, in reliance on applicable exemptions from registration, and will constitute “restricted securities”. Each Purchaser has represented to the Company that it is not affiliated with the Company or any of its directors or officers. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Masonglory Limited

Founded in 2018 in Hong Kong, Masonglory Limited is a subcontractor providing wet trades services and other ancillary services to property developers and Hong Kong government. As a registered specialist trade contractor (plastering-group 2) since 2020, the Company provides customers with comprehensive wet trades works solutions, which principally include: (i) plastering on floors, ceilings, and walls; (ii) tile laying on internal and external walls and floors; (iii) brick laying; (iv) floor screeding; and (v) marble works. For more information, please visit: https://www.masontech.com.hk/; https://ir.masontech.com.hk/

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “aim”, “anticipate”, “believe”, “estimate”, “expect”, “going forward”, “intend”, “may”, “plan”, “potential”, “predict”, “propose”, “seek”, “should”, “will”, “would” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

For more information, please contact:

Masonglory Limited

Investor Relations Department

Email: services@wealthfsllc.com

Complementary Transaction Supports Local Journalism in Arizona, Montana and South Dakota

DAVENPORT, Iowa, Sept. 28, 2026 (GLOBE NEWSWIRE) — Lee Enterprises, Incorporated (NASDAQ: LEE) and USA TODAY Co., Inc. (NYSE: TDAY) announced today strategic agreements that signal an exciting next chapter for both organizations, effective immediately. Lee Enterprises will acquire publications in South Dakota and Montana respectively to include the Sioux Falls Argus Leader, the Aberdeen American News (including the Farm Forum), the Watertown Public Opinion and the Great Falls Tribune. Lee Enterprises maintains a strong footprint across Montana through the Billings Gazette, Independent Record, Missoulian, The Montana Standard and Ravalli Republic, as well as the Rapid City Journal in South Dakota.

The agreements also conclude TNI Partners, the joint venture involving the Arizona Daily Star, where Lee Enterprises led the Arizona Daily Star’s newsroom, production and related technology operations, while USA TODAY Co. managed advertising and sales, accounting and finance functions. USA TODAY Co. will assume full ownership and operations of the Arizona Daily Star. This marks the beginning of a new chapter for local journalism and community engagement across Arizona where USA TODAY Co. owns The Arizona Republic.

These transactions allow each company to be better positioned to focus resources where they can have the greatest local impact. Aligning these trusted brands in these markets enables both companies to invest in growth, serve local audiences and support the future of community journalism.

“We’re honored to deepen our commitment to the communities of Montana and South Dakota,” said Nathan Bekke, Lee’s President and Chief Executive Officer. “Across the 193 brands we serve in 28 states, our focus is the same: providing trusted local news and information that helps people stay informed, connected and engaged in their communities.”

“These thoughtful transactions reflects a strategic decision to best serve these communities and support the future of local journalism,” said Michael A. Anastasi, Senior Vice President of Local News, USA TODAY Network. “As leaders in the industry, we have a responsibility to ensure local news organizations are positioned for long-term success. We are proud to welcome the Arizona Daily Star and its talented team to the USA TODAY Network and look forward to building on its longstanding tradition of trusted local journalism.”

ABOUT LEE ENTERPRISES, INC.

Lee Enterprises is a leading provider of local news and information and a major subscription and advertising platform with 193 owned and managed brands across 28 states. Lee’s markets include St. Louis, MO; Buffalo, NY; Omaha, NE; Richmond, VA; Lincoln, NE; Madison, WI; and Davenport, IA. Lee Common Stock is traded on NASDAQ under the symbol LEE. For more information about Lee, please visit www.lee.net.

ABOUT USA TODAY CO., INC.

USA TODAY Co., Inc. is a diversified media company with expansive reach at the national and local level dedicated to empowering and enriching communities. Our mission is to inspire, inform, and connect audiences. As a media and digital marketing solutions company we are focused on sustainable growth. Through our trusted brands, including the USA TODAY NETWORK, comprised of the national publication, USA TODAY, and our network of local properties, in the United States, and Newsquest, a wholly-owned subsidiary operating in the United Kingdom, we provide essential journalism, local content, and digital experiences to audiences and businesses. We deliver trusted unbiased journalism when and where consumers want it. LocaliQ, our digital marketing solutions brand, supports small and medium-sized businesses with innovative digital marketing products and solutions.

MEDIA CONTACTS

Lee Enterprises
IR@lee.net
(563) 383-2100

USA TODAY Co.
hgidaly@usatodayco.com

Complementary Transaction Supports Local Journalism in Arizona, Montana and South Dakota

DAVENPORT, Iowa, Sept. 28, 2026 (GLOBE NEWSWIRE) — Lee Enterprises, Incorporated (NASDAQ: LEE) and USA TODAY Co., Inc. (NYSE: TDAY) announced today strategic agreements that signal an exciting next chapter for both organizations, effective immediately. Lee Enterprises will acquire publications in South Dakota and Montana respectively to include the Sioux Falls Argus Leader, the Aberdeen American News (including the Farm Forum), the Watertown Public Opinion and the Great Falls Tribune. Lee Enterprises maintains a strong footprint across Montana through the Billings Gazette, Independent Record, Missoulian, The Montana Standard and Ravalli Republic, as well as the Rapid City Journal in South Dakota.

The agreements also conclude TNI Partners, the joint venture involving the Arizona Daily Star, where Lee Enterprises led the Arizona Daily Star’s newsroom, production and related technology operations, while USA TODAY Co. managed advertising and sales, accounting and finance functions. USA TODAY Co. will assume full ownership and operations of the Arizona Daily Star. This marks the beginning of a new chapter for local journalism and community engagement across Arizona where USA TODAY Co. owns The Arizona Republic.

These transactions allow each company to be better positioned to focus resources where they can have the greatest local impact. Aligning these trusted brands in these markets enables both companies to invest in growth, serve local audiences and support the future of community journalism.

“We’re honored to deepen our commitment to the communities of Montana and South Dakota,” said Nathan Bekke, Lee’s President and Chief Executive Officer. “Across the 193 brands we serve in 28 states, our focus is the same: providing trusted local news and information that helps people stay informed, connected and engaged in their communities.”

“These thoughtful transactions reflects a strategic decision to best serve these communities and support the future of local journalism,” said Michael A. Anastasi, Senior Vice President of Local News, USA TODAY Network. “As leaders in the industry, we have a responsibility to ensure local news organizations are positioned for long-term success. We are proud to welcome the Arizona Daily Star and its talented team to the USA TODAY Network and look forward to building on its longstanding tradition of trusted local journalism.”

ABOUT LEE ENTERPRISES, INC.

Lee Enterprises is a leading provider of local news and information and a major subscription and advertising platform with 193 owned and managed brands across 28 states. Lee’s markets include St. Louis, MO; Buffalo, NY; Omaha, NE; Richmond, VA; Lincoln, NE; Madison, WI; and Davenport, IA. Lee Common Stock is traded on NASDAQ under the symbol LEE. For more information about Lee, please visit www.lee.net.

ABOUT USA TODAY CO., INC.

USA TODAY Co., Inc. is a diversified media company with expansive reach at the national and local level dedicated to empowering and enriching communities. Our mission is to inspire, inform, and connect audiences. As a media and digital marketing solutions company we are focused on sustainable growth. Through our trusted brands, including the USA TODAY NETWORK, comprised of the national publication, USA TODAY, and our network of local properties, in the United States, and Newsquest, a wholly-owned subsidiary operating in the United Kingdom, we provide essential journalism, local content, and digital experiences to audiences and businesses. We deliver trusted unbiased journalism when and where consumers want it. LocaliQ, our digital marketing solutions brand, supports small and medium-sized businesses with innovative digital marketing products and solutions.

MEDIA CONTACTS

Lee Enterprises
IR@lee.net
(563) 383-2100

USA TODAY Co.
hgidaly@usatodayco.com

Issy-les-Moulineaux, September 28, 2026

Sodexo’s Board of Directors is proposing the appointment of Nathalie Bellon-Szabo as Chairwoman, subject to the renewal of her mandate at the Annual Shareholders Meeting on December 16, 2026. She would then succeed Sophie Bellon, who has served as Chairwoman of the Board of Directors since 2016.

After leading major strategic transformations over the past decade that have significantly reshaped Sodexo, including the spin-off and listing of its Benefits & Rewards services activity (Pluxee) and the divestment of Sodexo’s stake in Sofinsod, Sophie Bellon has decided not to seek renewal of her mandate as Chairwoman of the Board of Directors.

Throughout her tenure, Sophie Bellon strengthened both the independence of the Board and the quality of its work. She will now focus on Bellon SA, the family holding company, where she will become Chairwoman of the Management Board, while continuing to serve on Sodexo’s Board of Directors, subject to the renewal of her mandate by the Annual Shareholders Meeting.

The Board of Directors would like to extend its warmest thanks to Sophie Bellon for her commitment and her significant contribution to the Group’s transformation over the past ten years.

Nathalie Bellon-Szabo has dedicated most of her career to Sodexo. She has held numerous operational leadership roles and has been a member of the Group Executive Team since 2018. Under her leadership, Sodexo Live! has established itself as one of the global leaders in food services and travel hospitality across the sports, leisure and major events sectors, with revenue increasing fourfold over the past ten years, notably through its expansion in the United States, which has become its largest market. Today, Sodexo Live! is one of the Group’s key growth engines.

Nathalie Bellon-Szabo has served as a Director of Sodexo since 1989 and is a member of both the Nominating Committee and the Sustainability Committee. Her career has given her a deep understanding of the Group, its businesses, clients and teams, as well as extensive experience in its governance. She has also served as a Director of Pluxee since 2024, where she sits on the Nomination and Remuneration Committee, and as a Director of Bouygues Group since 2025.

Through this appointment, Nathalie Bellon-Szabo will become non-executive Chairwoman and will step down from her operational responsibilities within the company. Her role will be to lead the work of the Board of Directors, ensure high standards of governance, and enable the Board to support executive management.

This new phase in Sodexo’s governance comes as the Group enters a new chapter in its history with the launch of Shift & Grow 2030, its growth acceleration plan, in July 2026.

Sophie Bellon, Chairwoman of Sodexo’s Board of Directors:
  “I would like to warmly thank the members of the Board of Directors for their trust and for the quality of the work we have accomplished together in support of Sodexo’s transformation. After ten years as Chairwoman of the Board, I am particularly pleased that Nathalie will succeed me. Her operational experience and deep knowledge of Sodexo and its businesses will be invaluable assets in supporting the company through this new stage of its development. I wish her every success in her new role. ”

Nathalie Bellon-Szabo, future Chairwoman of Sodexo’s Board of Directors:
  “Over the past ten years, Sophie has played a pivotal role in preparing Sodexo for the future, and I would like to thank her. I would also like to thank the Board of Directors and my family for their trust. I bring to this role my deep commitment to our values and our mission, together with my strong conviction that value is created through growth. I fully appreciate the responsibility entrusted to me and will ensure that the Board supports Thierry Delaporte and his leadership team in executing the Group’s strategy. We share a common ambition: to accelerate Sodexo’s growth, remain ever closer to our clients, and further strengthen the Group’s position among the world’s leading companies in its industry.”

About Sodexo 
Founded in Marseille in 1966 by Pierre Bellon, Sodexo is the leader in Food and Services, shaping better everyday experiences at every moment in life: work, heal, learn and play. The Group stands out for its independence, its founding family shareholding and its responsible business model. With its services, Sodexo meets all the challenges of everyday life with a dual goal: to improve the quality of life of our employees and those we serve, and contribute to the economic, social and environmental progress in the communities where we operate. Our purpose is to create a better everyday for everyone to build a better life for all. Sodexo is included in the CAC Next 20, CAC SBT 1.5, FTSE 4 Good et DJSI indices. 
 

Key figures 

  • 24.1 billion euros Fiscal 2025 consolidated revenues 
  • 426,000 employees as at August 31, 2025 
  • #2 France-based private employer worldwide 
  • 43 countries 
  • 80 million consumers served daily 
  • 7.8 billion euro in market capitalization  
    (as July 15, 2026) 

Contacts

Media Analysts & investors
Mathieu Scaravetti Juliette Klein
+33 6 28 62 21 91 +33 1 57 75 80 27
mathieu.scaravetti@sodexo.com juliette.klein@sodexo.com


About Nathalie Bellon-Szabo

Nathalie Bellon-Szabo has been Chief Executive Officer of Sodexo Live! Worldwide and a member of Sodexo’s Group Executive Team since 2018.

Nathalie joined Sodexo in 1996 and was involved in the creation of Sodexo Prestige. She subsequently developed Sodexo’s Sports & Leisure business, which, under her leadership, became Sodexo Live! in 2021.

After initially serving as Sales Director of Sodexo Prestige in France, she became Chief Executive Officer of Sodexo Sports & Leisure France in 2010 and was appointed Chair of Lenôtre in 2012.

In 2015, she was appointed Chief Operating Officer of Sodexo’s Sports & Leisure business worldwide. She built a portfolio of premier client sites and prestigious brands spanning sports venues, major international events, MICE (Meetings, Incentives, Conferences and Events), as well as tourism, cultural destinations and airport lounges.

In 2017, Nathalie played a pivotal role in the acquisition of Centerplate in the United States, positioning Sodexo as a leading player in the sports and leisure industry and doubling its global footprint.

In 2018, she was appointed Chief Executive Officer of Sodexo’s Sports & Leisure business worldwide, joined Sodexo’s Group Executive Team and continued the worldwide expansion of the business, making Sodexo Live! one of the Group’s key growth engines. Today, Sodexo Live! operates across four continents: Europe, North America, Asia and Australia.

Throughout her career, Nathalie has demonstrated a strong commitment to talent development and internal promotion within both Sodexo Live! and Sodexo.

Nathalie graduated from the European Business School. She is a French and is fluent in English and Spanish.

Nathalie has served as a Director of Sodexo since 1989, Director of Pluxee since 2024, and Director of Bouygues Group since 2025.

Attachment

Issy-les-Moulineaux, September 28, 2026

Sodexo’s Board of Directors is proposing the appointment of Nathalie Bellon-Szabo as Chairwoman, subject to the renewal of her mandate at the Annual Shareholders Meeting on December 16, 2026. She would then succeed Sophie Bellon, who has served as Chairwoman of the Board of Directors since 2016.

After leading major strategic transformations over the past decade that have significantly reshaped Sodexo, including the spin-off and listing of its Benefits & Rewards services activity (Pluxee) and the divestment of Sodexo’s stake in Sofinsod, Sophie Bellon has decided not to seek renewal of her mandate as Chairwoman of the Board of Directors.

Throughout her tenure, Sophie Bellon strengthened both the independence of the Board and the quality of its work. She will now focus on Bellon SA, the family holding company, where she will become Chairwoman of the Management Board, while continuing to serve on Sodexo’s Board of Directors, subject to the renewal of her mandate by the Annual Shareholders Meeting.

The Board of Directors would like to extend its warmest thanks to Sophie Bellon for her commitment and her significant contribution to the Group’s transformation over the past ten years.

Nathalie Bellon-Szabo has dedicated most of her career to Sodexo. She has held numerous operational leadership roles and has been a member of the Group Executive Team since 2018. Under her leadership, Sodexo Live! has established itself as one of the global leaders in food services and travel hospitality across the sports, leisure and major events sectors, with revenue increasing fourfold over the past ten years, notably through its expansion in the United States, which has become its largest market. Today, Sodexo Live! is one of the Group’s key growth engines.

Nathalie Bellon-Szabo has served as a Director of Sodexo since 1989 and is a member of both the Nominating Committee and the Sustainability Committee. Her career has given her a deep understanding of the Group, its businesses, clients and teams, as well as extensive experience in its governance. She has also served as a Director of Pluxee since 2024, where she sits on the Nomination and Remuneration Committee, and as a Director of Bouygues Group since 2025.

Through this appointment, Nathalie Bellon-Szabo will become non-executive Chairwoman and will step down from her operational responsibilities within the company. Her role will be to lead the work of the Board of Directors, ensure high standards of governance, and enable the Board to support executive management.

This new phase in Sodexo’s governance comes as the Group enters a new chapter in its history with the launch of Shift & Grow 2030, its growth acceleration plan, in July 2026.

Sophie Bellon, Chairwoman of Sodexo’s Board of Directors:
  “I would like to warmly thank the members of the Board of Directors for their trust and for the quality of the work we have accomplished together in support of Sodexo’s transformation. After ten years as Chairwoman of the Board, I am particularly pleased that Nathalie will succeed me. Her operational experience and deep knowledge of Sodexo and its businesses will be invaluable assets in supporting the company through this new stage of its development. I wish her every success in her new role. ”

Nathalie Bellon-Szabo, future Chairwoman of Sodexo’s Board of Directors:
  “Over the past ten years, Sophie has played a pivotal role in preparing Sodexo for the future, and I would like to thank her. I would also like to thank the Board of Directors and my family for their trust. I bring to this role my deep commitment to our values and our mission, together with my strong conviction that value is created through growth. I fully appreciate the responsibility entrusted to me and will ensure that the Board supports Thierry Delaporte and his leadership team in executing the Group’s strategy. We share a common ambition: to accelerate Sodexo’s growth, remain ever closer to our clients, and further strengthen the Group’s position among the world’s leading companies in its industry.”

About Sodexo 
Founded in Marseille in 1966 by Pierre Bellon, Sodexo is the leader in Food and Services, shaping better everyday experiences at every moment in life: work, heal, learn and play. The Group stands out for its independence, its founding family shareholding and its responsible business model. With its services, Sodexo meets all the challenges of everyday life with a dual goal: to improve the quality of life of our employees and those we serve, and contribute to the economic, social and environmental progress in the communities where we operate. Our purpose is to create a better everyday for everyone to build a better life for all. Sodexo is included in the CAC Next 20, CAC SBT 1.5, FTSE 4 Good et DJSI indices. 
 

Key figures 

  • 24.1 billion euros Fiscal 2025 consolidated revenues 
  • 426,000 employees as at August 31, 2025 
  • #2 France-based private employer worldwide 
  • 43 countries 
  • 80 million consumers served daily 
  • 7.8 billion euro in market capitalization  
    (as July 15, 2026) 

Contacts

Media Analysts & investors
Mathieu Scaravetti Juliette Klein
+33 6 28 62 21 91 +33 1 57 75 80 27
mathieu.scaravetti@sodexo.com juliette.klein@sodexo.com


About Nathalie Bellon-Szabo

Nathalie Bellon-Szabo has been Chief Executive Officer of Sodexo Live! Worldwide and a member of Sodexo’s Group Executive Team since 2018.

Nathalie joined Sodexo in 1996 and was involved in the creation of Sodexo Prestige. She subsequently developed Sodexo’s Sports & Leisure business, which, under her leadership, became Sodexo Live! in 2021.

After initially serving as Sales Director of Sodexo Prestige in France, she became Chief Executive Officer of Sodexo Sports & Leisure France in 2010 and was appointed Chair of Lenôtre in 2012.

In 2015, she was appointed Chief Operating Officer of Sodexo’s Sports & Leisure business worldwide. She built a portfolio of premier client sites and prestigious brands spanning sports venues, major international events, MICE (Meetings, Incentives, Conferences and Events), as well as tourism, cultural destinations and airport lounges.

In 2017, Nathalie played a pivotal role in the acquisition of Centerplate in the United States, positioning Sodexo as a leading player in the sports and leisure industry and doubling its global footprint.

In 2018, she was appointed Chief Executive Officer of Sodexo’s Sports & Leisure business worldwide, joined Sodexo’s Group Executive Team and continued the worldwide expansion of the business, making Sodexo Live! one of the Group’s key growth engines. Today, Sodexo Live! operates across four continents: Europe, North America, Asia and Australia.

Throughout her career, Nathalie has demonstrated a strong commitment to talent development and internal promotion within both Sodexo Live! and Sodexo.

Nathalie graduated from the European Business School. She is a French and is fluent in English and Spanish.

Nathalie has served as a Director of Sodexo since 1989, Director of Pluxee since 2024, and Director of Bouygues Group since 2025.

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.